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Purpose: Multiple models have been developed to predict pathologic complete response (pCR) in
locally advanced rectal cancer patients. Unfortunately, validation of these models normally omit the
implications of cohort differences on prediction model performance. In this work, we will perform a
prospective validation of three pCR models, including information whether this validation will target
transferability or reproducibility (cohort differences) of the given models.
Methods: We applied a novel methodology, the cohort differences model, to predict whether a
patient belongs to the training or to the validation cohort. If the cohort differences model performs
well, it would suggest a large difference in cohort characteristics meaning we would validate the
transferability of the model rather than reproducibility. We tested our method in a prospective valida-
tion of three existing models for pCR prediction in 154 patients.
Results: Our results showed a large difference between training and validation cohort for one of the
three tested models [Area under the Receiver Operating Curve (AUC) cohort differences model:
0.85], signaling the validation leans towards transferability. Two out of three models had a lower
AUC for validation (0.66 and 0.58), one model showed a higher AUC in the validation cohort (0.70).
Discussion: We have successfully applied a new methodology in the validation of three prediction
models, which allows us to indicate if a validation targeted transferability (large differences between
training/validation cohort) or reproducibility (small cohort differences). © 2017 American Associa-
tion of Physicists in Medicine [https://doi.org/10.1002/mp.12423]
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1. INTRODUCTION
As the field of radiation oncology is moving towards individu-
alized medicine, the need to identify (sub-)groups of patients
on the basis of patient and/or tumor features is emerging.1
Machine learning techniques using (routine) clinical patient
information are needed to identify these features. Furthermore,
machine learning can be used to develop a prognostic model
for disease development, or to develop a predictive model
where the outcome may vary, based on the applied interven-
tion(s). These prognostic and predictive models are the build-
ing blocks for clinical decision support systems (CDSS).2 The
promise of these CDSSs is to handle and adapt to insights
found in research, relieving the clinical staff from the burden
of keeping up with the high volume of publications and the
rapidly increasing amount of knowledge.3,4
Before implementing clinical prediction models into a
CDSS, these models need validation on different levels.5
These levels can be classified using the TRIPOD statement.6
Although in many studies internal/external validations are
included, they normally do not describe validation results to
their full extent. According to Justice et al.7 validation of pre-
diction models should describe two aspects: Accuracy valida-
tion (performance of the model) and generalizability (how
similar/dissimilar are training and validation cohorts and why
and how do these differences influence the performance of
the model).
Accuracy, or model performance validation, describes the
statistical validity of a prognostic or predictive model.8 In
general, model performance (or fitness) is determined by the
discriminative ability and calibration of a prognostic/predic-
tive model.9 The discriminative ability describes how well a
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model correctly classifies a subject into the correct group.
Calibration describes the agreement of the frequency between
observed and predicted events.
The second aspect, generalizability, can be divided into
two components: reproducibility and transferability. Repro-
ducibility describes the accuracy of a prediction model on
similar cohorts, where transferability tests the accuracy of a
prediction model on cohorts with different characteristics.
Similarities or differences between two cohorts are affected
by temporal, methodological or geographic aspects.7 An
example of a temporal difference is the emerging influence of
HPV on head & neck cancer patients.10 Methodological dif-
ferences could originate from different treatments being
applied in the same patients or different levels of quality
(e.g., clinical routine versus clinical trials). Geographical dif-
ferent origins of the training and validation cohort could
make these different in, for example, race and socioeconomic
factors. Often these are interrelated with geographical differ-
ently located cancer centers treating different patients differ-
ently at different times.11,12 Often, (external) validation of
prediction models only describe the accuracy. The method
described by Debray et al.13 can be used to estimate the dif-
ference between the training and validation cohort, measuring
the level of generalizability (same characteristics) versus
transferability (different characteristics) between training and
validation cohorts. By adding this measurement, next to the
model performance on the validation set, it gives more insight
(without hard boundaries) in which situations a prediction
model does (not) work (Fig. 1). Therefore, it is imperative to
add this measure in the general model validation process, as
it better describes for which cohorts a prediction model was
tested.
In this work, we aim to investigate this reproducibility and
transferability metric in a prospective validation of three pre-
diction models for pathologic complete response (pCR) in
rectal cancer patients. These models have been developed
and retrospectively validated by van Stiphout et al.14 based
on prior work identifying prognostic factors for pathologic
response.15–17 We hypothesize that this prospective validation
tests for reproducibility, with comparable (or slightly
reduced) model performances.
2. METHOD AND MATERIALS
The three models we validated were learned on three dif-
ferent training cohorts as published previously.14 These mod-
els predict pathological complete response (pCR) based on
different groups of available data: (a) only clinically available
parameters (clinical model), (b) Clinically available parame-
ters + pretreatment PET parameters (pretreatment PET
model), (c) Clinically available parameter + pretreatment
PET + post-treatment PET parameters (post-treatment PET
model). For the PET parameters, tumors were semi-automati-
cally contoured on PET-CT scans using commercial software
(TrueD, Siemens Medical, Erlangen, Germany). Standardized
Uptake Value (SUV) thresholding was performed using the
gluteus muscle to set the threshold for the automatic contour-
ing, within pre-defined boundaries.18 The response index
(RI) describes the ratio between the pretreatment and post-
treatment SUV value of the primary tumor.14 Pathological
complete response was determined as having a T0N0M0
based on the surgical specimen, extracted from the pathology
report. Based on the three different datasets, an exhaustive
feature selection was performed to train a proximal Support
Vector Machine (SVM). Internal validation was performed
using a leave-one-out cross-validation.14 Original cohort data-
sets for training and validation were at our disposal. The
cohort used for our prospective validation was the THUN-
DER trial cohort (NCT00969657). This cohort consists of
154 patients, from two participating centers (MAASTRO
Clinic, Maastricht University Medical Centre+, Netherlands
and Sacred Heart University Hospital, Rome, Italy). All
patients included in this THUNDER trial gave written
informed consent before data was collected.
Univariate cohort differences were tested for statistical sig-
nificance using Wilcoxon rank sum test19 (for continuous
variables) or Fisher’s exact test20 (for categorical variables).
To correct for multiple (univariate) testing, we calculated an
adjusted P-value using the Bonferroni correction which mul-
tiplies the P-values by the number of comparisons. In our
case, multiplying the P-values by the number of model input
and output parameters. Cohort characteristics for the predic-
tion model variables are shown in Tables I, II and III.
Next, we calculated the multivariate cohort differences
(MCD) using the method proposed by Debray et al.13 This
method assesses the ability to predict whether a specific
patient in our cohort belongs to cohort A (training) or B (vali-
dation). When we are able to predict to which cohort patients
belong, it would mean that (several of) the underlying predic-
tion model variables have very different distributions (point-
ing to a validation which would test transferability). In
contrast, when we cannot predict to which cohort patients
belong, it would mean that the model variables are more
homogeneous among the training and validation cohort
FIG. 1. Model performance in perspective of validation performance. The x-
axis shows the cohort differences AUC (as described by Debray et al.13),
where the y-axis describes the model performance. Boundaries between
quadrants are only indicative.
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(which would be a validation set which is suitable to test
reproducibility). As this method predicts the originating
cohort for a specific patient, we can apply generic accuracy
validation measures; in this case we will use the Area under
the Receiver Operating Curve (AUC).21 In this situation, an
AUC close to 0.5 indicates no predictive performance and
hence little differences in cohort characteristics. An AUC
deviating from 0.5 will indicate differences in cohort charac-
teristics. We considered cohorts equal for an AUC = < 0.6,
moderately different between 0.6 and 0.8, and highly differ-
ent for an AUC > 0.8. To avoid confusion with the actual
evaluation of the prediction model, we will use the term
Cohort Differences AUC (CD-AUC) to denote the result of
the method explained above.
After performing tests to describe univariate and multi-
variate cohort differences, we compared the distributions of
predicted probabilities in the training and validation cohorts
by calculating mean probabilities and corresponding standard
deviations. Furthermore, we evaluated the prediction model
performance on both cohorts using the Area under the Recei-
ver Operating Curve (AUC),21 Hosmer-Lemeshow C-statis-
tic22 and Brier score23 to determine the discriminative ability,
calibration and accuracy, respectively.24,25 These perfor-
mance measures have different characteristics: The AUC
specifies the ability to make a threshold, separating the prob-
abilities for a given outcome into a binary yes/no result (dis-
criminative performance). Unfortunately, this AUC doesn’t
take the distance between a probability and the actually mea-
sured outcome into account, hence only determines the best
operating (threshold) point. In contrast, calibration measures
how well the predicted probability is comparable to the actual
incidence of the outcome. For example, the Hosmer–Leme-
show C-statistic splits patients into n groups, based on
ordered prediction probabilities, and uses the Chi-square test
to assess statistical significant differences between observed
and predicted outcomes.22 Finally, aspects from both discrim-
inative ability and calibration are available in accuracy mea-
surements. One of these measurements is the Brier score,
which is the mean squared error between probabilities and
the observed outcome.23 This score is not suitable as a single
measure; however is useful when comparing different models
with equal outcomes and/or cohorts.9 For more information
regarding these model performance metrics, we would like to
refer to Steyerberg et al.24
For robustness purposes, we used bootstrapping as a
resampling technique (R = 1000), and applied this method to
the discrimination (AUC) and accuracy (Brier score) mea-
surements. All calculations and statistical analysis were per-
formed using R26 (version 3.3.2). A generalized workflow of
the applied methods is shown in Fig. 2.
3. RESULTS
The multivariate cohort differences are shown in Table IV.
For every prediction model, we made a separate multivariate
TABLE I. Cohort characteristics clinical prediction model (pretreatment,
without PET features). The adjusted P-value determines a statistically signifi-
cant difference if < 0.05; based on the original training cohort, and current
(prospective) validation cohort. Wilcoxon rank sum test was used for contin-
uous variables, and Fisher’s exact test for categorical variables.
Variable Training
Validation
(pros) P-value
P-value
adjusted
# Patients 677 112
Tumor length
[cm] (SD)
4.97 (1.73) 5.03 (1.81) 9.63101 9.63101
cT 5.70109 2.28108
1 4 (0%) 0 (0%)
2 18 (3%) 16 (14%)
3 583 (86%) 70 (63%)
4 72 (11%) 26 (23%)
cN 1.45109 4.34108
0 154 (23%) 9 (8%)
1 307 (45%) 35 (31%)
2 216 (32%) 68 (61%)
pCR 134 (20%) 29 (26%) 1.6101 3.30101
TABLE II. Cohort characteristics pretreatment prediction model including
PET features. Tumor location measures the distance from the anal verge.
Variable Training Validation (pros) P-value
P-value
adjusted
# Patients 114 98
Max tumor
diameter
[cm] (SD)
7.01 (2.15) 5.70 (1.75) 3.14107 1.26106
cN 1.60107 7.99107
0 28 (24%) 8 (8%)
1 56 (49%) 28 (29%)
2 30 (26%) 62 (63%)
Tumor location 2.42106 7.27106
0–5 cm 56 (49%) 29 (30%)
5–10 cm 38 (33%) 15 (15%)
10–15 cm 20 (17%) 54 (55%)
SUV max (SD) 13.65 (6.23) 17.20 (8.29) 9.61104 1.92103
pCR 17 (15%) 25 (25%) 5.91102 5.91102
TABLE III. Cohort characteristics post-treatment prediction model (with PET
features).
Variable Training
Validation
(pros) P-value
P-value
adjusted
# Patients 107 53
Response index
SUV max
pre/post (SD)
56.79 (27.24) 63.32 (20.19) 2.9101 1
Tumor length
[cm] (SD)
5.54 (2.33) 5.12 (1.75) 3.5101 1
SUV max
(post-treatment) (SD)
5.94 (3.13) 5.25 (2.20) 3.6101 1
pCR 26 (24%) 13 (24%) 1 1
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model to predict whether a case belongs to the training or
validation cohort, and determined the AUC [further referred
as the Cohort Differences AUC (CD-AUC)]. The CD-AUCs
were 0.69, 0.85 and 0.62 for the clinical, pretreatment PET
and post-treatment PET prediction model variables,
respectively.
For the clinical prediction model, the multivariate differ-
ences model showed statistically significant differences in
clinical nodal stage and pCR. For the clinical + pretreatment
PET prediction model, the multivariate differences model
showed a high discriminative ability (CD-AUC: 0.85). In this
model, almost all variables showed a statistically significant
difference; except for pCR. Finally, for the clinical + pre-
and post-treatment PET prediction model, the multivariate
differences model had a low discriminative ability (CD-AUC:
0.62). None of the variables in this last model showed a statis-
tically significant difference.
Based on the CD-AUC values in Table IV, we can proba-
bly state that the clinical and pre–post PET prediction models
are being validated for reproducibility, where the pretreat-
ment PET prediction model is being validated for transfer-
ability. The CD-AUC of the pretreatment PET prediction
model indicated a high predictive ability whether a patient
belongs to the training/validation cohort. This is also
expressed in the (multivariate) cohort differences model coef-
ficients (Table IV) deviating from 0.
The comparison of distributions of predicted probabilities
in the training and validation cohorts for all three prediction
models are shown in Fig. 3. For the clinical + pretreatment
PET model, the mean and standard deviations for the pre-
dicted probabilities are almost equal in both training and vali-
dation cohorts. The post-treatment PET model shows a
higher average probability in the validation dataset, with a
smaller standard deviation. The latter could be due to the
small number of patients available for this prediction model.
After describing the (dis)similarity of training and valida-
tion cohorts, we will present the result of the model perfor-
mance on both cohorts. The prediction model performance
results for both cohorts are shown in Table V For both AUC
and Brier score, standard deviations (SD) are given, based on
bootstrapping the validation cohort. In addition, Figure 4 show
the calibration plots of predicted and observed outcomes for
both training and validation cohorts. For the clinical prediction
model, the AUC increased in the validation cohort, the
Hosmer–Lemeshow p-value showed a larger deviation from
perfect calibration (P-value < 0.05), and the Brier score
increased in the validation cohort (indicating a decrease in
overall model accuracy). For both pre- and post-treatment PET
model, validation metrics showed a similar trend with an
exception for the AUC (decrease instead of increase). For the
post-treatment PET model, the decrease in AUC was 2.8 times
the standard deviation in the validation. As this standard devia-
tion (0.10) was considered large, we would address this to the
distribution in probabilities described before (higher mean
probability; smaller standard deviation) and subsequently the
population size applicable for this prediction model.
4. DISCUSSION
The In this work, we have successfully performed a
prospective validation (TRIPOD statement6 type 4) of three
previously developed prediction models, and applied an addi-
tional method to assess the differences between training and
validation cohorts. In addition to the traditional accuracy vali-
dation, our analysis gives additional information to clinicians
whether the validation was performed on a similar or different
cohort (in terms of population characteristics), and therefore
whether the validation assessed the reproducibility (possible
same clinical setting), or transferability (possible different
clinical setting) of a prediction model. As these measures are
relatively easy to interpret, they could be used when commis-
sioning prognostic models for use in clinical practice, by
assessing whether the population in a certain clinic is differ-
ent from the population where the model was trained on.
We would advise to validate prediction models on trial and
routine clinical cohorts as also suggested by Booth and Tan-
nock27 and proposed in the VATE project.28,29 The quality of
cohorts from clinical trials are needed to identify which vari-
ables need to be reported in clinical practice. Afterwards,
training/validating models (using the methods explained
here) on routine clinical data would increase the cohorts
available to learn/validate upon as was done by Shen et al.30
Furthermore, validation in a clinical setting could also reduce
the turnaround time between developing/validating and using
predictive models in clinical practice; enabling rapid learning
healthcare and subsequently decision support.2,3
TABLE IV. Multivariate differences model for clinical, pretreatment PET and
post-treatment PET prediction model, based on original and current prospec-
tive validation cohort.
Variable Coefficient P-value
CD-AUC
(95% CI)
Clinical prediction model
Intercept 2.72 5.05104 0.69 (0.61–0.71)
Tumor length 0.04 5.09101
cT 0.11 6.69101
cN 1.01 5.65109
pCR 0.57 2.36102
Pretreatment PET prediction model
Intercept 1.32 1.23101 0.85 (0.78–0.89)
Max tumor diameter 0.51 5.18106
cN 1.36 1.06106
Tumor location 0.66 1.59103
SUV max 0.07 6.21103
pCR 0.81 8.31102
Post-treatment PET prediction model
Intercept 0.35 7.71101 0.62 (0.51–0.67)
Response index
SUV max pre/post
0.01 4.91101
Tumor length 0.09 3.35101
SUV max (post-treatment) 0.04 6.30101
pCR 0.31 4.69101
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When evaluating the results, the significance of the
univariate differences (P-values between training and valida-
tion cohort; Tables I, II and III) generally overlapped with the
multivariate cohort differences, described by the covariate
weight P-values (Table IV). But several variables which were
significant in the univariate variable assessment lost their sig-
nificance in the multivariate assessment (e.g., clinical T-
stage); or became significant (e.g., pCR). In our opinion, this
Validation 
cohort
Prediction 
model training 
cohort
Dataset 
Description
Multivariate 
Dataset 
Differences 
(MCD)
+
CD-AUC
Prediction 
Model 
Execution
Model 
performance:
Discrimination
Calibration
Accuracy
Cohort 
Differences 
Diagram
Interpret model performance
Considering
Generalizability or 
Transferability
FIG. 2. Generalized workflow for validation of existing prediction models, where model performance is put into respect of generalizability/transferability of the
evaluated prediction model. [Color figure can be viewed at wileyonlinelibrary.com]
TABLE V. Prediction performance results on both training and validation cohort for all three prediction models. Performance is measured in terms discrimination
(AUC; the higher the better), calibration (Hosmer–Lemeshow C-statistic); P-value > 0.05 the “better”) and accuracy (Brier score; the lower the better). For both
AUC and Brier score, standard deviations (SD) are given, based on bootstrapping the validation cohort.
Model AUC training (SD) Validation (SD)
H-L P-value
Brier training (SD) Validation (SD)Training Validation
Clinical 0.62 (0.03) 0.70 (0.06) 2.6102 4.2103 0.126 (0.008) 0.153 (0.021)
PET pre 0.74 (0.06) 0.66 (0.07) 1.2105 3.14102 0.118 (0.009) 0.149 (0.013)
PET post 0.86 (0.04) 0.58 (0.10) 8.4107 8103 0.135 (0.007) 0.164 (0.012)
FIG. 3. Diagrams displaying the differences between training and validation cohorts on different aspects. For both graphs, the y-axis represents differences in
cohort characteristics (CD-AUC). The x-axis shows the difference in mean probability of pCR (left figure, < 0 indicates lower mean probability in validation), or
ratio of standard deviations (SD, right figure, > 1.0 indicates larger SD in validation) in the training and validation cohort.
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could be affected by differences in sample sizes between
training and validation, or the effect of testing one variable
versus testing the complete characteristic of a patient.
Although this correlation reduces the added value of the
cohort differences metric, we still think this metric is an
added value as a single measure to assess cohort differences:
to determine whether external validation results measure
reproducibility or transferability. Secondly, statistical tests
only measure significant differences; the cohort differences
model can reveal subtle differences which only become
apparent in a multivariate analysis.
For the post-treatment PET model, our main hypothesis
is that the prediction model was overfitted on the training
cohort (pCR positive outcomes = 26). When calculating a
sample size for model training, we would use 10 events
per variable as used in this rule of thumb.31 As an exam-
ple, the training cohort would need 30, 40 and 30 events
(pCR) for the clinical, pretreatment PET and post-treament
PET model, respectively. When considering a pCR per-
centage of 20%, this would result in a population size of
150, 200 and 150 patients, respectively. As a result, only
the clinical prediction model training cohort would be
considered large enough. Regarding the validation cohort,
the only studies investigating model validation cohort sizes
up to our knowledge are by Collins et al.32 and Vergouwe
et al.33 They do state that 100 events would be a mini-
mum, meaning that the required sample size would be
500 patients, considering a pCR event rate of 20%. There-
fore we have to state that our validation might be under-
powered, however, could only be accomplished by large
multicenter trials. This also means that the cohort
difference model and AUC values cannot reliably detect a
difference in cohorts in underpowered datasets.
Future work would include the validation of the clini-
cal pCR prediction model in a routine clinical cohort,
and investigate applicability of prediction models in clini-
cal practice.
5. CONCLUSION
In general, we would advise to apply the explained meth-
ods when validating (existing) prediction models, as it puts
prediction model performance in perspective of the hetero-
geneity between training and validation cohorts. Our work-
flow (Fig. 1) could therefore be used as a guideline.
Based on these results, we can also state that the clinical
prediction model performed well when reproducing results in
the current prospective validation. The pre- and post-treat-
ment PET prediction models were unfortunately underpow-
ered in both training and validation cohorts.
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